Fatal disseminated bacillus Calmette-Guerin infection and arrested growth of cutaneous malignant melanoma following intralesional immunotherapy
- PMID: 3532854
- DOI: 10.1097/00000372-198608000-00010
Fatal disseminated bacillus Calmette-Guerin infection and arrested growth of cutaneous malignant melanoma following intralesional immunotherapy
Abstract
An 84-year-old man with aggressive cutaneous malignant melanoma, which failed to respond to systemic chemotherapy, was electively treated with intralesional bacillus Calmette-Guerin (BCG) immunotherapy. He died with widespread miliary granulomas, most likely representing disseminated BCG infection. However, at autopsy, the patient was found to have a minimal tumor burden and only a single focus of visceral metastatic malignant melanoma. In view of the clinically documented aggressive nature of this patient's disease, the arrested growth of his tumors is best attributed to the beneficial effect of BCG immunotherapy.
Similar articles
-
Granulomatous eruption after BCG vaccine immunotherapy for malignant melanoma.J Am Acad Dermatol. 1989 Nov;21(5 Pt 2):1119-22. doi: 10.1016/s0190-9622(89)70310-8. J Am Acad Dermatol. 1989. PMID: 2681298 Review.
-
Distant cutaneous granulomas after bacille Calmette-Guérin immunotherapy for malignant melanoma: case for direct infection.Clin Infect Dis. 1999 Dec;29(6):1569-70. doi: 10.1086/313543. Clin Infect Dis. 1999. PMID: 10585816 No abstract available.
-
Granulomas in melanoma patients treated with BCG immunotherapy.Cancer. 1982 Jan 1;49(1):55-60. doi: 10.1002/1097-0142(19820101)49:1<55::aid-cncr2820490113>3.0.co;2-f. Cancer. 1982. PMID: 7053820
-
Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene.Cancer. 1978 Jun;41(6):2456-63. doi: 10.1002/1097-0142(197806)41:6<2456::aid-cncr2820410654>3.0.co;2-b. Cancer. 1978. PMID: 657108 Clinical Trial.
-
Clinical and molecular insights into BCG immunotherapy for melanoma.J Intern Med. 2020 Dec;288(6):625-640. doi: 10.1111/joim.13037. Epub 2020 Mar 4. J Intern Med. 2020. PMID: 32128919 Review.
Cited by
-
Intralesional treatment for advanced melanoma: what's on the horizon?Melanoma Manag. 2016 Jun;3(2):113-123. doi: 10.2217/mmt-2016-0007. Epub 2016 May 25. Melanoma Manag. 2016. PMID: 30190880 Free PMC article. Review.
-
Intralesional therapy for advanced melanoma: promise and limitation.Curr Opin Oncol. 2015 Mar;27(2):151-6. doi: 10.1097/CCO.0000000000000158. Curr Opin Oncol. 2015. PMID: 25629369 Free PMC article. Review.
-
Hypotension and disseminated intravascular coagulation following intralesional bacillus Calmette-Guérin therapy for locally metastatic melanoma.Cancer Immunol Immunother. 1991;32(5):315-24. doi: 10.1007/BF01789050. Cancer Immunol Immunother. 1991. PMID: 1998973 Free PMC article.
-
Insights into the Molecular Mechanisms Behind Intralesional Immunotherapies for Advanced Melanoma.Cancers (Basel). 2020 May 22;12(5):1321. doi: 10.3390/cancers12051321. Cancers (Basel). 2020. PMID: 32455916 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical